Silence Therapeutics Plc
This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo.
Silence Therapeutics have developed proprietary modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutics. This allows the development of therapeutics for diseases with the high unmet clinical need. Silence’s technology is currently in the clinic in a Phase 2a pancreatic cancer trial.